Next Article in Journal
Wine Lees as Source of Antioxidant Molecules: Green Extraction Procedure and Biological Activity
Previous Article in Journal
Hyperoxia Disrupts Lung Lymphatic Homeostasis in Neonatal Mice
Previous Article in Special Issue
Differential Apoptotic Effects of Bee Product Mixtures on Normal and Cancer Hepatic Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

High Concentration of Protein Oxidation Biomarker O-Tyr/Phe Predicts Better Outcome in Childhood Bacterial Meningitis

by
Emilie Rugemalira
1,2,*,
Irmeli Roine
3,
Julia Kuligowski
4,
Ángel Sánchez-Illana
4,5,
José David Piñeiro-Ramos
4,
Sture Andersson
1,2,
Manuel Leite Cruzeiro
6,
Máximo Vento
4,7 and
Tuula Pelkonen
1,2,6,*
1
Children’s Hospital, Pediatric Research Center, Helsinki University Hospital, Stenbäckinkatu 9, 00029 Helsinki, Finland
2
Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00014 Helsinki, Finland
3
Faculty of Medicine, University Diego Portales, Avenida Manuel Rodríguez Sur 343, Santiago 8370109, Chile
4
Health Research Institute La Fe (IISLAFE), Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain
5
Department of Analytical Chemistry, University of Valencia, Dr. Moliner 50, 46100 Burjassot, Spain
6
Hospital Pediátrico David Bernardino, Rua Amilcar Cabral, Luanda, Angola
7
Division of Neonatology, University and Polytechnic Hospital La Fe (HULAFE), Avenida Fernando Abril Martorell 106, 46026 Valencia, Spain
*
Authors to whom correspondence should be addressed.
Antioxidants 2023, 12(3), 621; https://doi.org/10.3390/antiox12030621
Submission received: 6 February 2023 / Revised: 21 February 2023 / Accepted: 28 February 2023 / Published: 2 March 2023
(This article belongs to the Special Issue Antioxidants in Human Health and Disease)

Abstract

:
Neuronal damage in bacterial meningitis (BM) partly stems from the host´s inflammatory response and induced oxidative stress (OS). We studied the association of cerebrospinal fluid (CSF) biomarkers indicating oxidative damage to proteins with course of illness and outcome in childhood BM in Angola. Ortho-tyrosine/phenylalanine (o-Tyr/Phe), 3-chlorotyrosine/para-tyrosine (3Cl-Tyr/p-Tyr), and 3-nitrotyrosine/para-tyrosine (3NO2-Tyr/p-Tyr) concentration ratios were measured in 79 BM admission CSF samples, employing liquid chromatography coupled to tandem mass spectrometry. Besides death, disease outcomes were registered on Day 7 of treatment and one month after discharge (control visit). The outcome was graded according to the modified Glasgow Outcome Scale (GOS), which considers neurological and audiological sequelae. Children with a o-Tyr/Phe ratio below the median were more likely to present focal convulsions and secondary fever during recovery and suboptimal outcome (GOS < 5) on Day 7 and at control visit (odds ratio (OR) 2.85; 95% CI 1.14–7.14 and OR 5.23; 95% CI 1.66–16.52, respectively). Their most common sequela was ataxia on Day 7 and at control visit (OR 8.55; 95% CI 2.27–32.22 and OR 5.83; 95% CI 1.12–30.4, respectively). The association of a higher admission CSF o-Tyr/Phe ratio with a better course and outcome for pediatric BM points to a beneficial effect of OS.

1. Introduction

One of the key causes of neuronal damage in bacterial meningitis (BM) is bacterial toxin release and the host’s inflammatory response where oxidative/nitrosative stress plays a major pathophysiological role [1,2]. The bacterial stimulus in the subarachnoid space leads to a complex immunological cascade where cytokines and other inflammatory mediators are produced, consequently attracting polymorphonuclear leukocytes (PMNs) to the site. Amid the earliest inflammatory mediators released by PMN are large amounts of reactive oxygen and nitrogen species (ROS, RNS) that act as antimicrobials and generate oxidative/nitrosative stress, characterized as an imbalance of oxidant production and antioxidant defenses. This inflammatory reaction is beneficial for the defense against the infection but simultaneously deleterious as the pro-oxidant status can lead to structural or functional oxidative/nitrosative damage to proteins, DNA, and lipids. This can be assessed by the detection of specific biomarkers in the cerebrospinal fluid (CSF) [3,4].
The amino acid phenylalanine (Phe) can be used as a sentinel for protein damage because it has only one physiological end-product, para-tyrosine (p-Tyr), into which it is enzymatically oxidized by the action of phenylalanine hydroxylase. Under conditions of oxidative stress, the hydroxyl radical (∙OH) oxidizes the benzyl ring of Phe into the abnormal tyrosine isomers ortho-tyrosine (o-Tyr) and meta-tyrosine (m-Tyr), whereas p-Tyr is oxidized by peroxynitrite (ONOO−) into 3-nitrotyrosine (3NO2-Tyr) or by hypochlorous acid (HClO) into 3-chlorotyrosine (3Cl-Tyr). O-Tyr, m-Tyr, 3NO2-Tyr and 3Cl-Tyr are considered reliable biomarkers of oxidative protein damage [5]. The synthesis of the biomarkers is represented as figures in another context [6].
In addition to ROS, matrix metalloproteinases (MMPs) and the tissue inhibitor of metalloproteinases (TIMP)-1 contribute to the pathogenesis of BM brain damage. MMPs are proteolytic enzymes that take part in tissue destruction and remodeling, and act as modulators of inflammation [7]. Previous studies suggest a critical role for MMP-8 and MMP-9 as effectors of blood–brain barrier (BBB) damage [8,9] and, furthermore, oxidative stress as a trigger for the activation of MMPs [10].
If persistent, the inflammatory state in BM subsequently leads to decreased cerebral perfusion, cerebral oedema, raised intracranial pressure, metabolic disturbances, and vasculitis, all contributing to neuronal injury and ischemia [11]. If not fatal, there is roughly a 50% risk of short- and long-term neurological complications such as seizures, focal neurological deficits, hearing loss, cognitive impairment, hydrocephalus, learning disability and epilepsy [11].
In countries which include vaccination against Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae in their immunization programs, a decrease in the incidence of BM is observed [12]. For instance, in Angola, estimated by the Meningitis Progress Tracker by the World Health Organization, the under-five mortality rate for all cause BM has decreased from 82/100,000 in 2005 to 20/100,000 in 2019. The Hib and tridecavalent pneumococcal conjugate vaccine (PCV13) were implemented in Angola in 2006 and 2013, respectively. The widespread use of the meningococcal serogroup A (NmA) conjugate vaccine in the African meningitis belt countries started in 2010 and a continuous systematic surveillance shows that meningitis epidemics caused by NmA have not been reported for more than 10 years [13]. However, the BM case fatality rate has not changed significantly and may still reach 50%, with the largest concentrations of mortality remaining in the sub-Saharan Africa [14].
To further improve BM treatment and prognosis, a better understanding is needed of the pathophysiological events that occur after activation of the host´s inflammatory pathways. There is a substantial body of work indicating high CSF levels of reactive oxygen and nitrogen species, and of antioxidants in BM patients, but the literature is very heterogeneous as determination of their concentrations has been carried out by various means [3,15,16,17,18,19,20]. Our study group has assessed the oxidative/nitrosative stress occurring in pediatric BM patients by determining biomarkers indicating oxidative/nitrosative damage to proteins in the CSF at admission to hospital [6]. As a result, BM patients were clearly distinguished from non-BM patients, with ratios of o-Tyr/Phe, 3Cl-Tyr/p-Tyr, and 3NO₂-Tyr/p-Tyr being 570, 20, and 4.5 times as high, respectively.
Recently, BM research has focused on interventions aimed at reducing the inflammation. For now, dexamethasone is the only adjunctive therapy recommended by most guidelines in developed countries in community-acquired BM and mainly in adults [21]. Antioxidant treatments to counteract the reactive oxygen and nitrogen species released have been studied as adjuvant treatment, among other treatments, in experimental BM models, but not in patients [22,23]. Only a limited number of human studies are available on oxidative stress in relation to outcome [18,19,20,24]. Here, we aimed to study the relation of CSF protein oxidation biomarker levels to the course and outcomes of BM.

2. Materials and Methods

2.1. Patient Data

In this sequential pediatric study, the initial patient data were collected from a prospective single-center study carried out in the Pediatric Hospital of Luanda, Angola (2005–2008, ISRCTN62824827), that examined the effect of continuous β-lactam infusion and oral paracetamol on the outcome of BM without ultimately improving it (n = 723) [25].
CSF samples of study participants were taken on admission to hospital. BM was defined as confirmed when a child displayed signs and symptoms of BM and had either produced a positive CSF culture, CSF polymerase chain reaction result, a positive Gram-stain result, or a positive latex-agglutination test.
After primary CSF analysis, and whenever surplus was available, the samples were stored at −80 °C until further processing. Subsequent measurements could be performed on 79 CSF samples from confirmed BM patients. The details of Phe, p-Tyr, o-Tyr, 3Cl-Tyr, and 3NO₂-Tyr analysis were recovered employing liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and the results, as median concentrations, are illustrated in the first part of this sequential study [6]. The MMP-8 concentration (detection limit 0.08 ng/mL) was determined by a time-resolved immunofluorometric assay (IFMA) and the MMP-9, along with TIMP-1 concentrations, by an enzyme-linked immunosorbent assay; both methods were described previously [26,27].
Data on the patient history, admission status, and the course and outcome of illness were obtained. Besides death, disease outcome by predetermined criteria was registered on Day 7 of treatment and one month after discharge. First, the category “severe neurological sequelae” included blindness, quadriplegia, hydrocephalus requiring a shunt, and/or severe psychomotor retardation (not sitting/walking, speaking, or establishing contact, or requiring institutionalization), whereas “any neurological sequelae” covered these along with hemiparesis or monoparesis, ataxia (slight, moderate, or severe), and/or moderate psychomotor impairment. Second, hearing was registered with brainstem auditory evoked potentials using threshold levels of 40 dB, 60 dB, and 80 dB. Hearing was deemed impaired if the threshold stimulus at 40 dB remained undetected. The cutoff levels for moderate and severe hearing impairment were 60 dB and 80 dB, respectively. Finally, the outcome was graded according to the modified Glasgow Outcome Scale (GOS) in which score 1 indicates death; score 2, a vegetative state; score 3, severe disability (severe neurological sequelae and/or the better ear’s threshold above 80 dB); score 4, moderate disability (hemiparesis, moderate psychomotor retardation, or a hearing threshold for the better ear above 60 dB and no higher than 80 dB); and score 5, mild or no disability (monoparesis, ataxia, or a better-ear hearing threshold between 40 dB and 60 dB).

2.2. Statistical Analysis

The biomarker concentrations of o-Tyr, 3Cl-Tyr, and 3NO₂-Tyr were normalized with their corresponding precursors Phe and p-Tyr. Values below the limit of quantification (LOQ) were replaced by their corresponding 0.5 × LOQ. The biomarker concentration associations with patient baseline characteristics, course of illness and outcome measures were determined using Spearman’s rank correlation and the Mann–Whitney U-test, as appropriate. To evaluate the prognostic value of these associations, we then calculated the odds ratios (ORs) for an above- or below-median biomarker level with 95% confidence intervals (CIs). The statistical analysis was carried out with IBM SPSS Statistics 27.

2.3. Ethics

The study was conducted in accordance with the Declaration of Helsinki. The Luanda Children’s Hospital ethics committee approved the study in 2005, including the amendments for the current study. In the original studies, the participants were enrolled only after obtaining the consent of the legal guardian.

3. Results

3.1. Study Group

The median age of the patients was 12 months (IQR 7–42). Their median Glasgow Coma Score (GCS) at admission was 11 (IQR 7–14). A total of 60% (47/79) of the children had had seizures prior to admission and 43% (34/79) at admission. By Day 7, after the start of treatment, 35% (26/79) of the children had died, 57% (29/51) manifested neurological sequelae, 8% (4/48) manifested severe neurological sequelae, and 36% (16/45) had hearing impairment. The patient characteristics, CSF and blood sample results, and causative agents are illustrated in Table 1.

3.2. The Associations between o-Tyr/Phe Ratio and Admission Findings

The median o-Tyr/Phe ratio was 0.002 (IQR 0.001–0.013). A lower o-Tyr/Phe ratio (Supplemental digital content, Tables S1 and S2) distinguished boys from girls (p = 0.020) and characterized patients whose preadmission symptoms had lasted more than 3 days vs. less than 3 days (p = 0.047), and those with a history of preadmission/admission seizures vs. those with no seizures (p = 0.013 and p = 0.001, respectively).
A higher o-Tyr/Phe ratio correlated with a higher CSF leukocyte count (rho 0.384, p = 0.00047) and a higher admission axillary temperature (rho 0.229, p = 0.004). A lower o-Tyr/Phe ratio correlated with a higher CSF TIMP-1 level (rho −0.503, p < 0.0001) and a higher 3NO2/p-Tyr ratio (rho −0.351, p = 0.002).
Expressing the results in ORs (Table 2), the patients with an admission CSF o-Tyr/Phe ratio below the median were 4.35 (95% CI 1.67–11.33) times more likely to present with seizures on admission. They also had increased odds for showing a below-median CSF leukocyte count, an above-median TIMP-1 level, and an above-median 3NO2/p-Tyr ratio (OR 3.71; 95% CI 1.47–9.42, OR 8.70; 95% CI 3.16–23.99 and OR 5.25; 95% CI 2.01–13.70), respectively.

3.3. The Associations of o-Tyr/Phe Ratio with Course of Illness

The o-Tyr/Phe ratio was lower (Supplemental digital content, Table S3) in patients with seizures during hospital stay or focal seizures at any time during illness and in patients who had secondary fever subsequent to Day 7 after the start of treatment, compared with patients who did not present with seizures during hospital stay, have focal seizures during illness, or have secondary fever (p = 0.022, p = 0.039, and p = 0.009, respectively).
Expressed in ORs (Table 2), the children whose admission CSF o-Tyr/Phe ratio was below the median had an OR of 3.34 (95% CI 1.08–10.39) for having secondary fever and an OR of 2.86 (95% CI 1.14–7.16) for having focal seizures during illness.

3.4. The Associations of o-Tyr/Phe Ratio with Outcome

Although the median o-Tyr/Phe ratio was lower in patients who died within 24 h or by Day 7 after beginning treatment, the differences were not significant (p = 0.756 and p = 0.398, respectively: Supplemental digital content, Table S3).
However, the o-Tyr/Phe ratio was significantly lower (Supplemental digital content, Table S3) in patients with a suboptimal GOS (<5) on Day 7 of treatment and one month after discharge (p = 0.031 and 0.004), respectively). Likewise, the ratio was lower in patients with any neurological sequelae on Day 7 or one month after discharge (p = 0.0002 and p = 0.031, respectively) and in patients with ataxia on Day 7 of treatment or one month after discharge (p = 0.0002 and p = 0.015, respectively). Regarding hearing impairment, children showing severe hearing impairment after one month of discharge had a lower o-Tyr/Phe ratio compared with children with no, mild, or moderate hearing impairment (p = 0.021).
A better outcome with a higher GOS at one month after discharge correlated with a higher o-Tyr/Phe ratio (rho 0.271, p = 0.036). On the other hand, a lower o-Tyr/Phe ratio correlated with greater severity of ataxia on Day 7 of treatment and one month after discharge (rho −0.557, p = 0.0005 and rho −0.509, p = 0.004, respectively).
Expressed in ORs (Table 2), the children whose o-Tyr/Phe ratio was below the median presented odds of 2.85 (95% CI 1.14–7.14) and 5.23 (95% CI 1.66–16.52) for having a suboptimal GOS on Day 7 of treatment and one month after discharge, compared with children whose o-Tyr/Phe was above the median. The suboptimal result consisted of any neurological sequalae (OR 8.55; 95% CI 2.27–32.22 and OR 8.00; 95% CI 1.51–42.45 on Day 7 of treatment and one month after discharge, respectively), principally ataxia (OR 8.55; 95% CI 2.27–32.22 and OR 5.83; 95% CI 1.12–30.40 on Day 7 of treatment and one month after discharge, respectively).

3.5. The Associations of 3Cl-Tyr/p-Tyr Ratio with Findings on Admission, Course, and Outcome of Disease

The only significant finding concerning the ratio 3Cl-Tyr/p-Tyr was that its lower level correlated with a longer duration of preadmission illness (rho −0.281, p = 0.012).

3.6. The Associations of 3NO2-Tyr/p-Tyr Ratio with Findings on Admission, Course, and Outcome of Disease

A higher 3NO2-Tyr/p-Tyr ratio (Supplemental digital content, Table S1) correlated with a lower systolic blood pressure (rho −0.315, p = 0.009) and a lower GCS (rho −0.303, p = 0.007) on admission. In CSF, a higher ratio correlated with a lower leukocyte count and a lower MMP-8 concentration (rho −0.264, p = 0.019 and rho −0.233, p = 0.039, respectively), but a higher glucose concentration (rho 0.319, p = 0.004).
A higher 3NO2-Tyr/p-Tyr ratio indicated slower recovery by correlating with a longer duration with GCS under 15 (rho 0.224, p = 0.047).
Expressed in ORs (Table 3), the children whose 3NO2-Tyr/p-Tyr was above the median were 4.9 times (95% CI 1.441–16.664) more likely to have a GCS below 15 on admission, in addition to a below-median CSF leukocyte count (OR 2,976; 95% CI 1.192–7.433) and an above-median CSF glucose concentration (OR 2.56; 95% CI 1.028–6.375).

4. Discussion

Our findings show an association between a higher admission CSF o-Tyr/Phe ratio, reflecting a higher level of oxidative stress, and several indices attesting to a more favorable course of recovery and outcome from BM. Correspondingly, a lower admission o-Tyr/Phe ratio was associated with previously known patient admission and a course of illness characteristics that have been shown to correlate with poor outcome: low admission CSF leukocyte count, high TIMP-1, seizures, and secondary fever [28,29].
The current understanding is that the host´s excessive inflammatory reaction and further induced oxidative/nitrosative stress is highly responsible for the poor outcome in BM. Experimental studies have suggested radical scavengers and antioxidants as therapeutic options aimed at limiting BM associated neuronal injury [23]. Our results imply, on the contrary, a beneficial effect of oxidative stress on the outcome of BM, suggesting that the process is not as straightforward as assumed. For instance, an experimental study in rat pups found that treatment with the radical scavenger α-Phenyl-Tert-Butyl Nitrone (PBN) during S. pneumoniae meningitis attenuated cortical necrosis but increased apoptotic neuronal death in the hippocampus and further impaired learning when compared with saline-treated animals [30]. This was again in contrast with what was seen in GBS meningitis, in which PBN protected neurons from both forms of injury [31]. The authors of the former study suggested that pathogen- and host-related mechanisms that influence the redox status and transcription factors of neuronal cells could explain the protective vs. detrimental effects of the radical scavenger.
Findings concerning the biomarker ratio 3NO2-Tyr/p-Tyr showed an association between a higher level of it and slower recovery, but no direct association with outcome and somewhat conflicting results with severe disease. A higher admission 3NO2-Tyr/p-Tyr was associated with a lower CSF leukocyte count and a below-optimal GCS under 15, measures previously shown to indicate poor outcome. Moreover, a higher 3NO2-Tyr/p-Tyr ratio was associated with a lower admission o-Tyr/Phe ratio. This could suggest high 3NO2-Tyr/p-Tyr ratio as an indicator of poor outcome. Meanwhile, inconsistent with this is the association of high 3NO2-Tyr/p-Tyr ratio with a high CSF glucose since the opposite, low CSF glucose, is considered a predictor of poor outcome.
No associations were seen between admission 3Cl-Tyr/p-Tyr ratio and patient characteristics, course of illness, or outcome.
To date, there are only a few human BM studies available on oxidative/nitrosative stress in relation to outcome and even fewer involving protein oxidation/nitration. Jain et al. found that pediatric BM patients who died or had neurological sequelae had markedly elevated concentrations of cytokines (interleukin-1 beta and tumor necrosis factor alpha) and free radicals (O2˙, H2O2) compared with BM patients with survival without sequalae. [19]. In another BM study with adults, high 3NO₂-Tyr CSF concentrations were associated with unfavorable outcome, evaluated by GOS, at discharge [18]. To our knowledge, there are no human BM studies of o-Tyr or 3Cl-Tyr levels in association with outcome available.
We have no clear answers to explain the discrepancies between our study results and previous data, but we underline heterogenicities between them. Factors such as differences in the biomarkers measuring OS, time points of sampling, varying causative organisms, and outcome measures may play an explanatory role, at least to some degree.
A review by Ipson et al. [32] summarizes the literature of the toxicity of abnormal tyrosine isomers to cells and tissues (in aging and in disease states such as vascular diabetic disease and cataract in the human lens) and the possible mechanism by which this may occur. In many studies, the concentrations of abnormal tyrosine isomers correlated with other indicators of disease severity. Still, the authors state that the control of oxidative stress relies not only on the antioxidant capacity of the cell but also on its ability to eliminate stable but toxic radical adducts such as m-Tyr and o-Tyr. Only when both processes fail would the diseased state become evident. More data are needed to determine whether the formation or adverse effects of the tyrosine isomers differ between tissues.
Oxidative stress is implicated as a trigger for the activation of MMPs in numerous disease pathologies [33]. An experimental pneumococcal BM study suggested the activation of MMP-9 by ROS as a target for therapeutic intervention [10]. Our results did not show an association between CSF MMP-9 or MMP-8 levels and the protein oxidation biomarkers studied, but a clear negative correlation with o-Tyr/Phe ratio and TIMP-1 was seen. We could speculate that the low CSF TIMP-1 level enables a higher inflammatory state, in addition to the high CSF leukocyte level in correlation with high o-Tyr/Phe levels, and could indicate a type of pro-inflammatory state, favoring a good outcome.
We acknowledge study limitations which we addressed in the first part of this sequential pediatric study: the data used were from a study originally designed for other purposes. Hence, a sufficiently large CSF sample was available from only around 11% of the original series. When comparing the baseline characteristics of these two studies, we saw a difference only with pre-admission seizures: 70% (506/723) of the children had had seizures before admission in the whole study group, compared with 60% (47/79) in the current set (Supplemental material, Table S4). Access to a larger series of CSF samples, in addition to serial sampling and the study of changes in biomarker levels during treatment, together with concomitant data from other pro- and anti-inflammatory mediators, could give a better insight into the processes. Furthermore, many of the survivors were lost for follow-up, which was a challenge we anticipated in the resource-poor settings. It is possible that the most impaired children sought medical help after discharge and attended the follow-up, thus influencing the late outcome results.
The delay in seeking medical help was rather long in our study population, and the children were in poor condition on admission to hospital. The destructive activity in BM seems to appear early, and interventions aimed at preventing brain injury may have a very limited therapeutic window to be effective [22]. Hence, more effort is needed to increase the parents’ knowledge of the signs and symptoms of BM in order to reduce the delay before admission.
We conclude that a higher admission CSF o-Tyr/Phe ratio is associated with a better course of recovery, an outcome with fewer neurological sequelae (mainly ataxia), and a favorable GOS in pediatric BM patients. This study provides a new perspective on the host´s double-edged inflammatory reaction in terms of oxidative stress in the aim of finding new therapeutic approaches.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox12030621/s1. Table S1: Associations between admission cerebrospinal fluid (CSF) protein oxidation biomarker ratios o-Tyr/Phe, 3Cl-Tyr/p-Tyr, and 3NO2-Tyr/p-Tyr and baseline patient characteristics calculated using Spearman’s Rank correlation; Table S2: Associations between admission cerebrospinal fluid protein oxidation biomarker ratios o-Tyr/Phe, 3Cl-Tyr/p-Tyr, and 3NO2-Tyr/p-Tyr (median) and baseline patient characteristics calculated using the Mann–Whitney U-test; Table S3: Associations between admission cerebrospinal fluid protein oxidation biomarker ratios o-Tyr-Phe, 3Cl-Tyr/p-Tyr, and 3NO2-Tyr/p-Tyr (median) and course of illness and patient outcome calculated using the Mann–Whitney U-test.

Author Contributions

Conceptualization, T.P., M.V. and S.A.; methodology, M.V.; validation, M.V.; formal analysis, E.R., I.R.; investigation, T.P., M.L.C., J.K., Á.S.-I., J.D.P.-R.; resources, T.P., M.V.; writing—original draft preparation, E.R.; writing—review and editing, I.R., T.P., J.K, M.V., Á.S.-I.; visualization, E.R.; supervision, T.P.; project administration, T.P., M.V.; funding acquisition, T.P., M.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work: including the efforts of Emilie Rugemalira and Tuula Pelkonen, was supported by the Children’s Hospital, Pediatric Research Center, University of Helsinki, Helsinki University Hospital and Lastentautien Tutkimussäätiö (Foundation for Pediatric Research). This work, including the efforts of Julia Kuligowski, was supported by the Instituto de Carlos III Health Institute and co-funded by the European Union (grant number CPII21/00003). This work, including the efforts of Ángel Sánchez-Illana, was supported by RETICS (ref. RD16/0022/001) from Health Research Institute Carlos III, Spain, (ISCIII)-European Regional Development Fund (FEDER); the PFIS grant (ref. FI16/00380) from ISCIII (Ministry of Science and Innovation); and Margarita Salas grant (ref. UP2021-044-MS21-084) from the Ministry of Universities of the Government of Spain, financed by the European Union, NextGeneration EU. This work, including the efforts of Maximo Vento, was supported by RETICS funded by the PN 2018-2021 (Spain) ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (FEDER), reference RD16/0022.

Institutional Review Board Statement

The study was conducted in acccordance with the Declaration of Helsinki, and approved by the Luanda Children’s Hospital ethics committee (15 June 2005).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author. The data are nor publicly available due to patient-related confidentiality.

Acknowledgments

The authors thank the participating patients and their families in Luanda, Angola, for providing the data for the research.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Koedel, U.; Klein, M.; Pfister, H.-W. New Understandings on the Pathophysiology of Bacterial Meningitis. Curr. Opin. Infect. Dis. 2010, 23, 217–223. [Google Scholar] [CrossRef] [PubMed]
  2. Barichello, T.; Generoso, J.S.; Simões, L.R.; Elias, S.G.; Quevedo, J. Role of Oxidative Stress in the Pathophysiology of Pneumococcal Meningitis. Oxid. Med. Cell Longev. 2013, 2013, 371465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Srivastava, R.; Lohokare, R.; Prasad, R. Oxidative Stress in Children with Bacterial Meningitis. J. Trop. Pediatr. 2013, 59, 305–308. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Hamed, S.A.; Hamed, E.A.; Zakary, M.M. Oxidative Stress and S-100B Protein in Children with Bacterial Meningitis. BMC Neurol. 2009, 9, 51. [Google Scholar] [CrossRef] [Green Version]
  5. Davies, M.J.; Fu, S.; Wang, H.; Dean, R.T. Stable Markers of Oxidant Damage to Proteins and Their Application in the Study of Human Disease. Free Radic. Biol. Med. 1999, 27, 1151–1163. [Google Scholar] [CrossRef]
  6. Rugemalira, E.; Roine, I.; Kuligowski, J.; Sánchez-Illana, Á.; Piñeiro-Ramos, J.D.; Andersson, S.; Peltola, H.; Leite Cruzeiro, M.; Pelkonen, T.; Vento, M. Protein Oxidation Biomarkers and Myeloperoxidase Activation in Cerebrospinal Fluid in Childhood Bacterial Meningitis. Antioxidants 2019, 8, 441. [Google Scholar] [CrossRef] [Green Version]
  7. Leppert, D.; Lindberg, R.L.; Kappos, L.; Leib, S.L. Matrix Metalloproteinases: Multifunctional Effectors of Inflammation in Multiple Sclerosis and Bacterial Meningitis. Brain Res. Brain Res. Rev. 2001, 36, 249–257. [Google Scholar] [CrossRef]
  8. Leppert, D.; Leib, S.L.; Grygar, C.; Miller, K.M.; Schaad, U.B.; Holländer, G.A. Matrix Metalloproteinase (MMP)-8 and MMP-9 in Cerebrospinal Fluid during Bacterial Meningitis: Association with Blood-Brain Barrier Damage and Neurological Sequelae. Clin. Infect. Dis. 2000, 31, 80–84. [Google Scholar] [CrossRef] [Green Version]
  9. Paul, R.; Lorenzl, S.; Koedel, U.; Sporer, B.; Vogel, U.; Frosch, M.; Pfister, H.W. Matrix Metalloproteinases Contribute to the Blood-Brain Barrier Disruption during Bacterial Meningitis. Ann. Neurol. 1998, 44, 592–600. [Google Scholar] [CrossRef]
  10. Meli, D.N.; Christen, S.; Leib, S.L. Matrix Metalloproteinase-9 in Pneumococcal Meningitis: Activation via an Oxidative Pathway. J. Infect. Dis. 2003, 187, 1411–1415. [Google Scholar] [CrossRef] [Green Version]
  11. Zainel, A.; Mitchell, H.; Sadarangani, M. Bacterial Meningitis in Children: Neurological Complications, Associated Risk Factors, and Prevention. Microorganisms 2021, 9, 535. [Google Scholar] [CrossRef] [PubMed]
  12. McIntyre, P.B.; O’Brien, K.L.; Greenwood, B.; van de Beek, D. Effect of Vaccines on Bacterial Meningitis Worldwide. Lancet 2012, 380, 1703–1711. [Google Scholar] [CrossRef] [PubMed]
  13. Viviani, S. Efficacy and Effectiveness of the Meningococcal Conjugate Group A Vaccine MenAfriVac® in Preventing Recurrent Meningitis Epidemics in Sub-Saharan Africa. Vaccines 2022, 10, 617. [Google Scholar] [CrossRef]
  14. GBD 2016 Meningitis Collaborators Global, Regional, and National Burden of Meningitis, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018, 17, 1061–1082. [CrossRef] [PubMed] [Green Version]
  15. Tsukahara, H.; Haruta, T.; Todoroki, Y.; Hiraoka, M.; Noiri, E.; Maeda, M.; Mayumi, M. Oxidant and Antioxidant Activities in Childhood Meningitis. Life Sci. 2002, 71, 2797–2806. [Google Scholar] [CrossRef] [PubMed]
  16. Ray, G.; Aneja, S.; Jain, M.; Batra, S. Evaluation of Free Radical Status in CSF in Childhood Meningitis. Ann. Trop. Paediatr. 2000, 20, 115–120. [Google Scholar] [CrossRef] [PubMed]
  17. Miric, D.; Katanic, R.; Kisic, B.; Zoric, L.; Miric, B.; Mitic, R.; Dragojevic, I. Oxidative Stress and Myeloperoxidase Activity during Bacterial Meningitis: Effects of Febrile Episodes and the BBB Permeability. Clin. Biochem. 2010, 43, 246–252. [Google Scholar] [CrossRef]
  18. Kastenbauer, S.; Koedel, U.; Becker, B.F.; Pfister, H.W. Oxidative Stress in Bacterial Meningitis in Humans. Neurology 2002, 58, 186–191. [Google Scholar] [CrossRef]
  19. Jain, M.; Aneja, S.; Mehta, G.; Ray, G.N.; Batra, S.; Randhava, V.S. CSF Interleukin-1 Beta, Tumor Necrosis Factor-Alpha and Free Radicals Production in Relation to Clinical Outcome in Acute Bacterial Meningitis. Indian Pediatr. 2000, 37, 608–614. [Google Scholar]
  20. Namiduru, E.S.; Namiduru, M.; Karaoğlan, İ.; Koçak, K. Oxidative and Nitrosative Stress in Patients with Meningitis. Eur. J. Clin. Exp. Med. 2022, 20, 70–74. [Google Scholar] [CrossRef]
  21. Nau, R.; Djukic, M.; Spreer, A.; Ribes, S.; Eiffert, H. Bacterial Meningitis: An Update of New Treatment Options. Expert Rev. Anti. Infect. Ther. 2015, 13, 1401–1423. [Google Scholar] [CrossRef] [PubMed]
  22. Liechti, F.D.; Grandgirard, D.; Leib, S.L. Bacterial Meningitis: Insights into Pathogenesis and Evaluation of New Treatment Options: A Perspective from Experimental Studies. Future Microbiol. 2015, 10, 1195–1213. [Google Scholar] [CrossRef] [PubMed]
  23. Klein, M.; Koedel, U.; Pfister, H.-W. Oxidative Stress in Pneumococcal Meningitis: A Future Target for Adjunctive Therapy? Prog. Neurobiol. 2006, 80, 269–280. [Google Scholar] [CrossRef] [PubMed]
  24. Tsukahara, H.; Haruta, T.; Ono, N.; Kobata, R.; Fukumoto, Y.; Hiraoka, M.; Mayumi, M. Oxidative Stress in Childhood Meningitis: Measurement of 8-Hydroxy-2’-Deoxyguanosine Concentration in Cerebrospinal Fluid. Redox Rep. 2000, 5, 295–298. [Google Scholar] [CrossRef]
  25. Pelkonen, T.; Roine, I.; Cruzeiro, M.L.; Pitkäranta, A.; Kataja, M.; Peltola, H. Slow Initial β-Lactam Infusion and Oral Paracetamol to Treat Childhood Bacterial Meningitis: A Randomised, Controlled Trial. Lancet Infect. Dis. 2011, 11, 613–621. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Lindberg, R.L.P.; Sorsa, T.; Tervahartiala, T.; Hoffmann, F.; Mellanen, L.; Kappos, L.; Schaad, U.B.; Leib, S.L.; Leppert, D. Gelatinase B [Matrix Metalloproteinase (MMP)-9] and Collagenases (MMP-8/-13) Are Upregulated in Cerebrospinal Fluid during Aseptic and Bacterial Meningitis in Children. Neuropathol. Appl. Neurobiol. 2006, 32, 304–317. [Google Scholar] [CrossRef]
  27. Tuomainen, A.M.; Nyyssönen, K.; Laukkanen, J.A.; Tervahartiala, T.; Tuomainen, T.-P.; Salonen, J.T.; Sorsa, T.; Pussinen, P.J. Serum Matrix Metalloproteinase-8 Concentrations Are Associated with Cardiovascular Outcome in Men. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 2722–2728. [Google Scholar] [CrossRef]
  28. Teixeira, D.C.; Diniz, L.M.O.; Guimarães, N.S.; Moreira, H.M.D.A.S.; Teixeira, C.C.; Romanelli, R.M.D.C. Risk Factors Associated with the Outcomes of Pediatric Bacterial Meningitis: A Systematic Review. J. Pediatr. 2020, 96, 159–167. [Google Scholar] [CrossRef]
  29. Roine, I.; Pelkonen, T.; Bernardino, L.; Lauhio, A.; Tervahartiala, T.; Lappalainen, M.; Kataja, M.; Pitkäranta, A.; Sorsa, T.; Peltola, H. Predictive Value of Cerebrospinal Fluid Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Concentrations in Childhood Bacterial Meningitis. Pediatr. Infect. Dis. J. 2014, 33, 675–679. [Google Scholar] [CrossRef]
  30. Loeffler, J.M.; Ringer, R.; Hablützel, M.; Täuber, M.G.; Leib, S.L. The Free Radical Scavenger Alpha-Phenyl-Tert-Butyl Nitrone Aggravates Hippocampal Apoptosis and Learning Deficits in Experimental Pneumococcal Meningitis. J. Infect. Dis. 2001, 183, 247–252. [Google Scholar] [CrossRef] [Green Version]
  31. Leib, S.L.; Kim, Y.S.; Chow, L.L.; Sheldon, R.A.; Täuber, M.G. Reactive Oxygen Intermediates Contribute to Necrotic and Apoptotic Neuronal Injury in an Infant Rat Model of Bacterial Meningitis Due to Group B Streptococci. J. Clin. Investig. 1996, 98, 2632–2639. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Ipson, B.R.; Fisher, A.L. Roles of the Tyrosine Isomers Meta-Tyrosine and Ortho-Tyrosine in Oxidative Stress. Ageing Res. Rev. 2016, 27, 93–107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Nelson, K.K.; Melendez, J.A. Mitochondrial Redox Control of Matrix Metalloproteinases. Free Radic. Biol. Med. 2004, 37, 768–784. [Google Scholar] [CrossRef] [PubMed]
Table 1. Patient characteristics, admission cerebrospinal fluid, and blood sample results.
Table 1. Patient characteristics, admission cerebrospinal fluid, and blood sample results.
CharacteristicsResults
Patients
Number of patients79
Age in months, median (IQR)12 (7–42)
Female sex (%)41/79 (48%)
Weight for age, z-score below −219 (24%)
History of present illness
Duration of illness in days, median (IQR)4 (3–7)
Previous antibiotics *30/74 (41%)
Preadmission seizures47/79 (60%)
Findings on admission
Seizures at admission34/79 (43%)
Glasgow coma score, median (IQR)11 (7–14) a
Another focus of infection19/79 (24%)
Cerebrospinal fluid
Leukocyte count (×10⁶/L), median (IQR)1740 (353–3515)
Glucose concentration (mg/dL), median (IQR)16.7 (9.1–26.3) b
o-Tyr/Phe, median (IQR)0.002 (0.001−0.013)
3Cl-Tyr/p-Tyr, median (IQR)0.007 (0.003−0.022)
3NO2-Tyr/p-Tyr, median (IQR)0.001 (0.001−0.002)
MMP-8, (ng/mL), median (IQR)481 (271–1076)
MMP-9, (ng/mL), median (IQR)514 (205–1239)
TIMP-1 (ng/mL), median (IQR)317 (100–1586)
Blood
C-reactive protein on Day 1 or 2 (mg/L), median ** (IQR)154 (81–161) c
Glucose (mg/dL), median (IQR) ***85 (62–111) d
Hemoglobin Day 1 or 2 (g/dL), median (IQR)7.5 (6–9) e
Causative agent
Streptococcus pneumoniae40/79 (51%)
Haemophilus influenzae type b24/79 (30%)
Neisseria meningitidis11/79 (14%)
a n = 78, b n = 78, c n = 34, d n = 75 and e n = 77. * Number of patients for whom data were available are shown. ** When CRP level exceeded 160mg/L, it was marked as 161mg/L. *** Lowest glucose on Day 1. The biomarker ratios of 3Cl-Tyr/p-Tyr, 3NO2-Tyr/p-Tyr and 3NO2-Tyr/p-Tyr originate from units of nmol/l.
Table 2. The odds ratios (OR) with 95% confidence intervals of a child with bacterial meningitis whose admission cerebrospinal fluid (CSF) o-Tyr/Phe was below the median (0.0015) in relation to patient findings on admission, course of illness, and outcome.
Table 2. The odds ratios (OR) with 95% confidence intervals of a child with bacterial meningitis whose admission cerebrospinal fluid (CSF) o-Tyr/Phe was below the median (0.0015) in relation to patient findings on admission, course of illness, and outcome.
CharacteristicOR95% CIp Value
Admission patient findings
Male0.420.17–1.030.058
Seizures prior to admission2.500.98–6.180.056
Seizures on admission4.351.67–11.330.003
CSF leukocyte count below median3.711.47–9.420.006
TIMP-1 level above median8.703.16–23.99<0.0001
3NO2-Tyr/p-Tyr above median5.252.012–13.6980.0007
Course of illness
Secondary fever after Day 73.341.08–10.390.037
Seizures during hospital stay2.320.89–6.030.085
Focal seizures during illness2.861.14–7.160.025
Outcome
Ataxia
On Day 7 of treatment (n = 51)8.552.27–32.220.002
One month after discharge (n = 31)5.831.12–30.400.036
Moderate or severe ataxia
On Day 7 of treatment (n = 47)5.511.58–19.270.008
One month after discharge (n = 30)18.671.90–185.40.012
Any neurological sequelae
On Day 7 of treatment (n = 48)8.552.27–32.220.002
One month after discharge8.001.51–42.450.015
Glasgow Outcome Score below 5
On Day 7 of treatment (n = 78)2.851.14–7.140.026
One month after discharge (n = 60)5.231.66–16.520.005
Table 3. The odds ratios (OR) with 95% confidence intervals (95% CI) of a child with bacterial meningitis whose admission cerebrospinal fluid (CSF) 3NO2-Tyr/p-Tyr was above the median (0.001) in relation to patient findings on admission, course of illness. and outcome.
Table 3. The odds ratios (OR) with 95% confidence intervals (95% CI) of a child with bacterial meningitis whose admission cerebrospinal fluid (CSF) 3NO2-Tyr/p-Tyr was above the median (0.001) in relation to patient findings on admission, course of illness. and outcome.
CharacteristicOR95% CIp Value
Systolic blood pressure below median1.0710.150–7.6420.945
GCS below optimal on admission *4.901.441–16.6640.011
CSF leukocyte count below median2.9761.192–7.4330.020
CSF glucose above median2.561.028–6.3750.043
MMP-8 below median1.2890.533–3.1210.573
* Glasgow coma scale score below 15.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rugemalira, E.; Roine, I.; Kuligowski, J.; Sánchez-Illana, Á.; Piñeiro-Ramos, J.D.; Andersson, S.; Cruzeiro, M.L.; Vento, M.; Pelkonen, T. High Concentration of Protein Oxidation Biomarker O-Tyr/Phe Predicts Better Outcome in Childhood Bacterial Meningitis. Antioxidants 2023, 12, 621. https://doi.org/10.3390/antiox12030621

AMA Style

Rugemalira E, Roine I, Kuligowski J, Sánchez-Illana Á, Piñeiro-Ramos JD, Andersson S, Cruzeiro ML, Vento M, Pelkonen T. High Concentration of Protein Oxidation Biomarker O-Tyr/Phe Predicts Better Outcome in Childhood Bacterial Meningitis. Antioxidants. 2023; 12(3):621. https://doi.org/10.3390/antiox12030621

Chicago/Turabian Style

Rugemalira, Emilie, Irmeli Roine, Julia Kuligowski, Ángel Sánchez-Illana, José David Piñeiro-Ramos, Sture Andersson, Manuel Leite Cruzeiro, Máximo Vento, and Tuula Pelkonen. 2023. "High Concentration of Protein Oxidation Biomarker O-Tyr/Phe Predicts Better Outcome in Childhood Bacterial Meningitis" Antioxidants 12, no. 3: 621. https://doi.org/10.3390/antiox12030621

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop